Reviewer's report

Title: Follow-up of Phase I Trial of Adalimumab and Rosiglitazone in FSGS: III. Report of the FONT Study Group

Version: 1 Date: 16 November 2009

Reviewer: Pankaj Hari

Reviewer's report:

The authors have tried to assess a very important long term outcome parameter to demonstrate the antifibrotic effect of the newer therapies rosiglitazone and adalimumab.

1. However the numbers are quite small to draw meaningful conclusions.

2. With very small number of patients comparison between the two treatments is futile and irrelevant.

3. A major drawback of the study is that the patients after the 16 wk FONT therapies were on uncontrolled treatments which could result in the beneficial effect shown on GFR in the study. The authors should provide the details of the treatment received by these patients during the follow-up which should be compared with the treatment received prior to institution of FONT therapy, in particular ACEI and statins.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests